ResearchMoz

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted

GBI Research
Published Date » 2011-11-22
No. Of Pages » 216

GBI Research, the leading business intelligence provider, has released its latest research Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted which provides an insight into different endpoints that are used for the central nervous system (CNS) in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed central nervous system drugs with an emphasis on safety and efficacy details. Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.

The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increased geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development and is expected to fulfill the unmet needs in the CNS disease market. The product pipeline for multiple sclerosis has many orally administered novel molecules whereas for alzheimers disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 that target the underlying causes of the disease and thus may offer significant benefits to the patients. 

The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years the market will witness patent expiries of major drugs, however this will be offset by the rapid uptake of new molecules, which will stabilize the market decline. The market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.

This report details Endpoints Clinical Trials in Central nervous system Disorders, highlighting the five major central nervous system disorders which are Alzheimers disease, Depression, Epilepsy, Parkinsons disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.

Scope

  • Data and analysis on the marketed products and analysis of their efficacy and safety details
  • Analysis of the five major Central nervous system diseases which include Alzheimers disease, depression, epilepsy, Parkinsons disease and schizophrenia
  • Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
  • Analysis on most promising molecules of five major central nervous system diseases with emphasis on their efficacy and safety details.
  • Company Profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

  • Understand the trends in clinical trial endpoints used for central nervous system diseases
  • Build effective strategies to launch their pipeline products by identifying the right endpoints
  • Understanding and applying Surrogate endpoints and Clinical Biomarkers as endpoints for central nervous system diseases
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7

2 Clinical Trial Design in Central Nervous System - Overview 12
2.1 Introduction 12
2.2 Types of Clinical Trial Outcomes 12
2.2.1 Primary Outcomes 12
2.2.2 Secondary Outcomes 12
2.3 GBI Research Report Guidance 13

3 Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling 14
3.1 Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval 14
3.1.1 Alzheimers disease 15
3.1.2 Depression 15
3.1.3 Epilepsy 16
3.1.4 Parkinsons disease 16
3.1.5 Schizophrenia 17

4 Endpoints - Clinical Trials in CNS Disorders Marketed and Pipeline Product Assessments 18
4.1 Alzheimers disease 18
4.1.1 Primary Endpoints used in Alzheimers disease Clinical Trials 19
4.1.2 Secondary Endpoints used in Alzheimers disease Clinical Trials 19
4.1.3 Major Marketed Drugs-Safety and Efficacy Analysis 19
4.1.4 Phase III Clinical Trial Analysis 25
4.1.5 Most Promising Drugs Profiles 41
4.1.6 Phase II Clinical Trial Analysis 45
4.1.7 Terminated Trials Analysis 61
4.2 Depression 62
4.2.1 Primary Endpoints used in Clinical Trials for Depression 63
4.2.2 Secondary Endpoints used in Clinical Trials for Depression 63
4.2.3 Major Marketed Drugs-Safety and Efficacy Analysis 64
4.2.4 Phase III Clinical Trial Analysis 70
4.2.5 Most Promising Drugs Profiles 79
4.2.6 Phase II Clinical Trial Analysis 81
4.2.7 Terminated Trials Analysis 87
4.3 Epilepsy 88
4.3.1 Primary Endpoints used in Clinical Trials for Epilepsy 89
4.3.2 Secondary Endpoints used in Clinical Trials for Epilepsy 90
4.3.3 Major Marketed Drugs-Safety and Efficacy Analysis 90
4.3.4 Phase III Clinical Trial Analysis 96
4.3.5 Most Promising Drugs Profiles 108
4.3.6 Phase II Clinical Trial Analysis 114
4.3.7 Terminated Trials Analysis 122
4.4 Parkinsons disease 123
4.4.1 Primary Endpoints used in Clinical Trials for Parkinsons disease 123
4.4.2 Secondary Endpoints used in Clinical Trials Parkinsons disease 124
4.4.3 Major Marketed Drugs-Safety and Efficacy Analysis 124
4.4.4 Phase III Clinical Trial Analysis 130
4.4.5 Most Promising Drugs Profiles 144
4.4.6 Phase II Clinical Trial Analysis 149
4.4.7 Terminated Trials Analysis 162
4.5 Schizophrenia 163
4.5.1 Primary Endpoints used in Clinical Trials for Schizophrenia 164
4.5.2 Secondary Endpoints used in Clinical Trials for Schizophrenia 164
4.5.3 Major Marketed Drugs-Safety and Efficacy Analysis 165
4.5.4 Phase III Clinical Trial Analysis 171
4.5.5 Most Promising Drugs Profiles 188
4.5.6 Phase II Clinical Trial Analysis 191
4.5.7 Terminated Trials Analysis 200

5 Endpoints - Clinical Trials in CNS Disorders - Company Profiles 201
5.1 Pfizer Inc. 201
5.1.1 Company Profile 201
5.1.2 Major Central Nervous System Disorders Products 201
5.2 GlaxoSmithKline Plc 202
5.2.1 Company Profile 202
5.2.2 Major Central Nervous System Disorders Products 202
5.3 AstraZeneca Plc 203
5.3.1 Company Profile 203
5.3.2 Major Central Nervous System Disorders Products 203
5.4 Sanofi 204
5.4.1 Company Profile 204
5.4.2 Major Central Nervous System Disorders Products 204
5.5 Johnson & Johnson 205
5.5.1 Company Profile 205
5.5.2 Major Central Nervous System Disorders Products 205
5.6 Eli Lilly and Company 207
5.6.1 Company Profile 207
5.6.2 Major Central Nervous System Disorders Products 207
5.7 Novartis AG 208
5.7.1 Company Profile 208
5.7.2 Major Central Nervous System Disorders Products 208
5.8 Abbott Laboratories 210
5.8.1 Company Profile 210
5.8.2 Major Central Nervous System Disorders Products 210
5.9 Forest Laboratories, Inc 211
5.9.1 Company Profile 211
5.9.2 Major Central Nervous System Disorders Products 211
5.10 Eisai Co., Ltd 212
5.10.1 Company Profile 212
5.10.2 Major Central Nervous System Disorders Products 212

6 Endpoints - Clinical Trials in CNS Disorders - Appendix 213
6.1 Market Definitions 213
6.2 Abbreviations 213
6.3 Research Methodology 214
6.3.1 Clinical Trial Design Overview 215
6.3.2 Marketed and Pipeline Products Assessment 215
6.3.3 Company Profiles 215
6.4 Contact Us 216
6.5 Disclaimer 216
6.6 Sources 216

List of Tables


Table 1: Endpoints - Clinical Trials in CNS Disorders, Alzheimers disease, Endpoints for Major Marketed Drugs, Global,1990- 2010 15
Table 2: Endpoints - Clinical Trials in CNS Disorders, Depression, Endpoints for Major Marketed Drugs, Global,1990- 2010 15
Table 3: Endpoints - Clinical Trials in CNS Disorders, Epilepsy, Endpoints for Major Marketed Drugs, Global,1990- 2010 16
Table 4: Endpoints - Clinical Trials in CNS Disorders, Parkinsons disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010 16
Table 5: Endpoints - Clinical Trials in CNS Disorders, Parkinsons disease, Endpoints for Major Marketed Drugs, Global, 1990- 2010 17
Table 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 32
Table 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 40
Table 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 52
Table 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 60
Table 10: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Alzheimers Disease 61
Table 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010 76
Table 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Primary Endpoints, Global, 2000-2010 79
Table 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase III Trial Molecules, Secondary Endpoints, Global, 2000-2010 79
Table 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 85
Table 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 87
Table 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 87
Table 17: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Depression 87
Table 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 101
Table 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 108
Table 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 119
Table 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Primary Endpoints, Global, 2000-2010 121
Table 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Trial Molecules, Secondary Endpoints, Global, 2000-2010 121
Table 23: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Epilepsy 122
Table 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 136
Table 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 143
Table 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 155
Table 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 161
Table 28: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Parkinsons Disease 162
Table 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 178
Table 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 187
Table 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 194
Table 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Trial Molecules, Primary & Secondary Endpoints, Global, 2000-2010 199
Table 33: Endpoints- Clinical Trials in Central Nervous System Disorders, List of Terminated Drugs for Schizophrenia 200
Table 34: Endpoints- Clinical Trials in Central Nervous Disorders, Pfizer Inc, Major Central Nervous Drugs, 2010 201
Table 35: Endpoints- Clinical Trials in Central Nervous Disorders, GlaxoSmithKline Plc, Major Central Nervous Drugs, 2010 202
Table 36: Endpoints- Clinical Trials in Central Nervous Disorders, AstraZeneca Plc, Major Central Nervous Drugs, 2010 203
Table 37: Endpoints- Clinical Trials in Central Nervous Disorders, Sanofi, Major Central Nervous Drugs, 2010 204
Table 38: Endpoints- Clinical Trials in Central Nervous Disorders, Johnson & Johnson, Major Central Nervous Drugs, 2010 205
Table 39: Endpoints- Clinical Trials in Central Nervous Disorders, Eli Lilly & Company, Major Central Nervous Drugs, 2010 207
Table 40: Endpoints- Clinical Trials in Central Nervous Disorders, Novartis AG, Major Central Nervous Drugs, 2010 208
Table 41: Endpoints- Clinical Trials in Central Nervous Disorders, Abbott Laboratories, Major Central Nervous Drugs, 2010 210
Table 42: Endpoints- Clinical Trials in Central Nervous Disorders, Forest Laboratories, Inc., Major Central Nervous Drugs, 2010 211
Table 43: Endpoints- Clinical Trials in Central Nervous Disorders, Eisai Co., Inc., Major Central Nervous Drugs, 2010 212

List of Figures


Figure 1: Endpoints - Clinical Trials in CNS Disorders, Number of Pipeline products in Phase III Stage of Development, 2011 13
Figure 2: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 24
Figure 3: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 25
Figure 4: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 26
Figure 5: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 27
Figure 6: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Rare Secondary Endpoints, Global, 2000-2010 28
Figure 7: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 29
Figure 8: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 30
Figure 9: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 34
Figure 10: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 35
Figure 11: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 36
Figure 12: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 37
Figure 13: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 38
Figure 14: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 44
Figure 15: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 45
Figure 16: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 46
Figure 17: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 47
Figure 18: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 48
Figure 19: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 49
Figure 20: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 50
Figure 21: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 54
Figure 22: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 55
Figure 23: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 56
Figure 24: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 57
Figure 25: Endpoints- Clinical Trials in Central Nervous System Disorders, Alzheimers Disease, Ongoing Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 58
Figure 26: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 69
Figure 27: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 70
Figure 28: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 71
Figure 29: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 72
Figure 30: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 73
Figure 31: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 74
Figure 32: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 80
Figure 33: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 81
Figure 34: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 82
Figure 35: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 83
Figure 36: Endpoints- Clinical Trials in Central Nervous System Disorders, Depression, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 84
Figure 37: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 95
Figure 38: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 96
Figure 39: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 97
Figure 40: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 98
Figure 41: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 99
Figure 42: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 104
Figure 43: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 105
Figure 44: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 106
Figure 45: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 113
Figure 46: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 114
Figure 47: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 115
Figure 48: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 116
Figure 49: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 117
Figure 50: Endpoints- Clinical Trials in Central Nervous System Disorders, Epilepsy, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 120
Figure 51: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 129
Figure 52: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 130
Figure 53: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 131
Figure 54: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 132
Figure 55: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 133
Figure 56: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase III Clinical Trials Classified Based on Rare Multiple Secondary Endpoints, Global, 2000-2010 134
Figure 57: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 139
Figure 58: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 140
Figure 59: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 141
Figure 60: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 148
Figure 61: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 149
Figure 62: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 150
Figure 63: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 151
Figure 64: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 152
Figure 65: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 153
Figure 66: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Completed Phase II Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 154
Figure 67: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 157
Figure 68: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 158
Figure 69: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 159
Figure 70: Endpoints- Clinical Trials in Central Nervous System Disorders, Parkinsons Disease, Ongoing Phase II Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 160
Figure 71: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 170
Figure 72: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 171
Figure 73: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 172
Figure 74: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Primary Endpoints, Global, 2000-2010 173
Figure 75: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 174
Figure 76: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Secondary Endpoints, Global, 2000-2010 175
Figure 77: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 176
Figure 78: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase III Clinical Trials Classified Based on Other Multiple Secondary Endpoints, Global, 2000-2010 177
Figure 79: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 184
Figure 80: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 185
Figure 81: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase III Clinical Trials Classified Based on Multiple Secondary Endpoints, Global, 2000-2010 186
Figure 82: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 190
Figure 83: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Other Primary Endpoints, Global, 2000-2010 191
Figure 84: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Multiple Primary Endpoints, Global, 2000-2010 192
Figure 85: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Completed Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 193
Figure 86: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Primary Endpoints, Global, 2000-2010 197
Figure 87: Endpoints- Clinical Trials in Central Nervous System Disorders, Schizophrenia, Ongoing Phase II Clinical Trials Classified Based on Secondary Endpoints, Global, 2000-2010 198

Upcoming Reports:

Treatment For Syndromes Of Dementia And Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trend And Forecast 2013 - 2019
By - Transparency Market Research
Dementia is a serious brain disorder or damage which leads to memory loss, language and thinking ability. The global market for treatments for syndromes of Dementia is witnessing a significant growth in last few years. Rapid technological advancement with increasing number of research in the area of Dementia and other movement disorders are supporting growth to the market. Many pharmaceutical companies are collaborating with research institutes in order to develop new and advanced treatment for syndromes of dementia.  The global market for treatments for syndromes of Dementia...
Medical Education Market: Global Industry Analysis, Size, Share And Forecast, 2012 - 2018
By - Transparency Market Research
Medical education is the term associated with the practice of working as a medical practitioner either for initial training to become a doctor or for additional training after gaining the degree. Medical education market actors includemedical schools, health program providers, nursing programs providers, and such others. Continuous growth in world population and rising awareness towards personal health is creating the need for seeking medical education, either for working as a medical practitioner or for personal care.  Global market for medical education is on...
Greece: market of plastic doors and windows
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the plastic doors and windows market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the plastic doors and windows market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...